CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
CCTG is happy to welcome Carol Hill who will be supporting the IND program as a Patient Representative.
Over the last six months, Centre Representatives and Contact CRAs at Canadian CCTG participating centres have been asked to share some of the challenges they’ve been experiencing around patient accrual and trial activations. This has included a Virtual Road Show of six 90-minute regional sessions and two surveys to supplement Road Show discussions and attempt to drill down on specific issues impacting accrual and trial activations, including around funding that may be impacting centres’ ability and capacity to activate and enroll patients to trials.
The Canadian Cancer Trials Group (CCTG) has now activated the symptom control trial SC29 evaluating high precision stereotactic body radiotherapy (SBRT) to conventional palliative radiotherapy (CRT) for patients with advanced cancer and a painful non-spine bone metastasis. SBRT represents a high dose treatment typically offered in the curative cancer setting; however, its role as a palliative treatment to improve pain for these patients is unknown.
The Canadian Cancer Trials Group (CCTG) is requesting applications for the volunteer position of Chair of the Patient Representative Committee.
